AbbVie Loses Monopoly Protection for Humira After Years of Gaming the U.S. Patent System
January 31, 2023 — In response to news that pharmaceutical giant AbbVie is losing its monopoly protection for Humira — a crucial anti-inflammatory treatment and highest-grossing drug in the world — six years after its key patent was supposed to expire, the American Economic Liberties Project released the following statement.
Economic Liberties Launches New Site to Organize Support for FTC’s Proposed Ban on Noncompetes
January 31, 2023 — The American Economic Liberties Project today launched BanNoncompetes.org, a new website that provides a clear and easy way for the millions of workers, small business owners, and entrepreneurs affected by noncompete agreements to voice their support of the Federal Trade Commission’s proposed ban.
U.S. Court of Appeals Blocks Bad Faith Bankruptcies
January 30, 2023 — In response to news that the Third Circuit rejected Johnson & Johnson’s appeal of a ruling dismissing its subsidiary bankruptcy filing, the American Economic Liberties Project released the following statement.
The Biden Administration Can Only Achieve Its Laudable “Worker-Centered” Trade Policy for the Americas by Fixing the Existing U.S. Trade Deals with Most Prospective APEP Partners and Building On Solid New Foundations
January 27, 2023 — As USTR Katherine Tai and Secretary of State Tony Blinken hosted a virtual ministerial meeting revealing initial countries interested in negotiating on a proposed Americas Partnership for Economic Prosperity (APEP), Rethink Trade Director Lori Wallach released the following statement.
Jim Jordan Is a Big Tech Ally
January 27, 2023 — In response to news that Republican leader Representative Jim Jordan is kicking Freedom Caucus co-founder Representative Ken Buck from his position as the lead Republican on the Antitrust Subcommittee, the American Economic Liberties Project released the following statement.